Masonic Cancer Center, University of Minnesota: Myeloproliferative Disorders trials
The registry lists 10 Myeloproliferative Disorders studies with Masonic Cancer Center, University of Minnesota as lead sponsor. 2 are open to participants now and 5 have results posted.
Phase 1 3Phase 2 8No phase 2(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- Allo HSCT Using RIC and PTCy for Hematological DiseasesRecruitingNCT05805605Phase 2
- Myeloablative Allo HSCT With Related or Unrelated Donor for Heme DisordersRecruitingNCT03314974Phase 2
- PTCy + Sirolimus/VIC-1911 as GVHD Prophylaxis in Myeloablative PBSC TransplantationCompletedNCT05120570Phase 1/2Results posted
- UCB Transplant for Hematological Diseases Using a Non Myeloablative PrepCompletedNCT02722668Phase 2Results posted
- Preservation of Ovarian Function After Hematopoietic Cell TransplantTerminatedNCT01343368Phase 2Results posted
- Non-Myeloablative Conditioning for Unrelated Donor Umbilical Cord Blood TransplantCompletedNCT00305682Phase 2Results posted
- Donor Umbilical Cord Blood Transplant By Injection Into the Bone Marrow in Treating Patients With Hematologic CancerTerminatedNCT00295880Phase 1/2Results posted
- T-Regulatory Cell and CD3 Depleted Double Umbilical Cord Blood Transplantation in Hematologic MalignanciesWithdrawnNCT01163201Phase 1/2
- Chemotherapy and Total-Body Irradiation Followed by Donor Umbilical Cord Blood Transplant, Cyclosporine, and Mycophenolate Mofetil in Treating Patients With Hematologic CancerCompletedNCT00290641Not applicable
- Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic CancerTerminatedNCT00290628Not applicable